Background
Sarcopenia and functional impairment are common and lethal extra-hepatic manifestations of cirrhosis. We aimed to determine the association between computed-tomography (CT)-based measures of muscle mass and quality (sarcopenia) and performance-based measures of muscle function.
Methods
Adults listed for liver transplant underwent testing of muscle function [grip strength, Short Physical Performance Battery (SPPB)] within 3 months of abdominal CT. Muscle mass (cm2/m2) =total cross-sectional area of psoas, paraspinal, and abdominal wall muscles at L3 on CT, normalized for height. Muscle quality=mean Hounsfield units (HU) for total skeletal muscle area at L3.
Results
Among 292 candidates, median grip strength was 31kg, SPPB score was 11, muscle mass was 49cm2/m2, and muscle quality was 35HU. Grip strength weakly correlated with muscle mass (ρ=0.26, p<0.001) and quality (ρ=0.27; p<0.001) in men, and muscle quality (ρ=0.23, p=0.02), but not muscle mass, in women. SPPB correlated weakly with muscle quality in men (ρ=0.38; p<0.001) and women (ρ=0.25; p=0.02), however did not correlate with muscle mass in men or women. After adjustment for gender, MELD-Na, hepatocellular carcinoma, and BMI, grip strength (HR 0.74, 95%CI 0.59–0.92, p=0.008), SPPB (HR 0.89, 95%CI 0.82–0.97, p=0.01), and muscle quality (HR 0.77, 95%CI 0.63–0.95, p=0.02) were associated with wait-list mortality, but muscle mass was not (HR 0.91, 95%CI 0.75–1.11, p=0.35).
Conclusions
Performance-based tests of muscle function are only modestly associated with CT-based muscle measures. Given that they predict wait-list mortality and can be conducted quickly and economically, tests of muscle function may have greater clinical utility than CT-based measures of sarcopenia.